{"id":571,"date":"2025-10-01T13:00:45","date_gmt":"2025-10-01T13:00:45","guid":{"rendered":"https:\/\/wickedsister.evit.com.au\/index.php\/2025\/10\/01\/ectrims-2025-frexalimab-shows-long-term-benefits-for-ms-patients\/"},"modified":"2025-10-01T13:00:45","modified_gmt":"2025-10-01T13:00:45","slug":"ectrims-2025-frexalimab-shows-long-term-benefits-for-ms-patients","status":"publish","type":"post","link":"https:\/\/wickedsister.evit.com.au\/index.php\/2025\/10\/01\/ectrims-2025-frexalimab-shows-long-term-benefits-for-ms-patients\/","title":{"rendered":"ECTRIMS 2025: Frexalimab shows long-term benefits for MS patients"},"content":{"rendered":"<p><a href=\"https:\/\/multiplesclerosisnewstoday.com\/ectrims\/2025\/10\/01\/ectrims-2025-frexalimab-safely-maintains-disease-control-ms-long-term\/\" title=\"ECTRIMS 2025: Frexalimab shows long-term benefits for MS patients\" rel=\"nofollow\"><img loading=\"lazy\" decoding=\"async\" width=\"800\" height=\"298\" src=\"https:\/\/multiplesclerosisnewstoday.com\/wp-content\/uploads\/2023\/10\/ECTRIMS-4-800x298.png\" class=\"webfeedsFeaturedVisual wp-post-image\" alt=\"A map of Europe is shown alongside the word &quot;ECTRIMS.&quot;\" style=\"margin: auto;margin-bottom: 15px;max-width: 100%\" data-wp-pid=\"128856\" \/><\/a><\/p>\n<p>Frexalimab, a therapy Sanofi is developing for multiple sclerosis (MS) patients, led to sustained reductions in disease activity in people with relapsing forms of MS over more than two years [&#8230;]<\/p>\n<p>The post <a href=\"https:\/\/multiplesclerosisnewstoday.com\/ectrims\/2025\/10\/01\/ectrims-2025-frexalimab-safely-maintains-disease-control-ms-long-term\/\">ECTRIMS 2025: Frexalimab shows long-term benefits for MS patients<\/a> appeared first on <a href=\"https:\/\/multiplesclerosisnewstoday.com\">Multiple Sclerosis News Today<\/a>.<\/p>\n<p><em>Source: <a href=\"https:\/\/multiplesclerosisnewstoday.com\/ectrims\/2025\/10\/01\/ectrims-2025-frexalimab-safely-maintains-disease-control-ms-long-term\/\" rel=\"nofollow noopener\" target=\"_blank\">multiplesclerosisnewstoday.com<\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Frexalimab, a therapy Sanofi is developing for multiple sclerosis (MS) patients, led to sustained reductions in disease activity in people with relapsing forms of MS over more than two years [&#8230;] The post ECTRIMS 2025: Frexalimab shows long-term benefits for MS patients appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com<\/p>\n","protected":false},"author":0,"featured_media":572,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[11,15,9,8,13,14,12,10],"class_list":["post-571","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-multiple-sclerosis-research","tag-brain-repair","tag-marburg-type-ms","tag-ms","tag-multiple-sclerosis","tag-myelin","tag-neuroregeneration","tag-oligodendrocyte","tag-remyelination"],"_links":{"self":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/571","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/comments?post=571"}],"version-history":[{"count":0,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/571\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/media\/572"}],"wp:attachment":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/media?parent=571"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/categories?post=571"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/tags?post=571"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}